Athira Pharma ^Peer

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Bothell, Washington. Founded in 2011 and formerly known as M3 Biotechnology, the company focuses on advancing therapies for neuronal health. Athira Pharma is publicly traded on NASDAQ under the ticker symbol ATHA.

The company's mission is to restore lives by developing small molecules aimed at treating neurological disorders and slowing neurodegeneration. Athira's product pipeline includes several drug candidates, such as ATH-1017, which is in Phase 2/3 clinical trials for Alzheimer's disease, and ATH-1105, currently in Phase 1 trials for amyotrophic lateral sclerosis (ALS). The company utilizes proprietary neurotrophic factor technology to create innovative therapeutic solutions for neurodegenerative diseases.